

CLAIMS

We claim:

1. A targeting construct comprising:
 - 5 (a) a first polynucleotide sequence homologous to a low density lipoprotein-related protein 5 gene;
 - (b) a second polynucleotide sequence homologous to the low density lipoprotein-related protein 5 gene; and
 - (c) a selectable marker.
- 10 2. The targeting construct of claim 1, wherein the targeting construct further comprises a screening marker.
- 15 3. A method of producing a targeting construct, the method comprising:
 - (a) providing a first polynucleotide sequence homologous to a low density lipoprotein-related protein 5 gene;
 - (b) providing a second polynucleotide sequence homologous to the low density lipoprotein-related protein 5;
 - (c) providing a selectable marker; and
 - (d) inserting the first sequence, second sequence, and selectable marker into a vector, to produce the targeting construct.
- 20 4. A method of producing a targeting construct, the method comprising:
 - (a) providing a polynucleotide comprising a first sequence homologous to a first region of a low density lipoprotein-related protein 5 gene and a second sequence homologous to a second region of a low density lipoprotein-related protein 5 gene;
 - (b) inserting a positive selection marker in between the first and second sequences to form the targeting construct.
- 25 5. A cell comprising a disruption in a low density lipoprotein-related protein 5 gene.
6. The cell of claim 5, wherein the cell is a murine cell.
7. The cell of claim 6, wherein the murine cell is an embryonic stem cell.
- 30 8. A non-human transgenic animal comprising a disruption in a low density lipoprotein-related protein 5 gene.

9. A cell derived from the non-human transgenic animal of claim 8.

10. A method of producing a transgenic mouse comprising a disruption in a low density lipoprotein-related protein 5 gene, the method comprising:

- 5 (a) introducing the targeting construct of claim 1 into a cell;
- (b) introducing the cell into a blastocyst;
- (c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and
- (d) breeding the chimeric mouse to produce the transgenic mouse.

11. A method of identifying an agent that modulates the expression of a low density lipoprotein-related protein 5, the method comprising:

- 10 (a) providing a non-human transgenic animal comprising a disruption in a low density lipoprotein-related protein 5 gene;
- (b) administering an agent to the non-human transgenic animal; and
- (c) determining whether the expression of low density lipoprotein-related protein 5 in the non-human transgenic animal is modulated.

12. A method of identifying an agent that modulates the function of a low density lipoprotein-related protein 5, the method comprising:

- 15 (a) providing a non-human transgenic animal comprising a disruption in a low density lipoprotein-related protein 5 gene;
- (b) administering an agent to the non-human transgenic animal; and
- (c) determining whether the function of the disrupted low density lipoprotein-related protein 5 gene in the non-human transgenic animal is modulated.

13. A method of identifying an agent that modulates the expression of low density lipoprotein-related protein 5, the method comprising:

- 20 (a) providing a cell comprising a disruption in a low density lipoprotein-related protein 5 gene;
- (b) contacting the cell with an agent; and
- (c) determining whether expression of the low density lipoprotein-related protein 5 is modulated.

30 14. A method of identifying an agent that modulates the function of a low density lipoprotein-related protein 5 gene, the method comprising:

(a) providing a cell comprising a disruption in a low density lipoprotein-related protein 5 gene;
(b) contacting the cell with an agent; and
(c) determining whether the function of the low density lipoprotein-related protein 5 gene is modulated.

5 15. The method of claim 13 or claim 14, wherein the cell is derived from the non-human transgenic animal of claim 8.

16. An agent identified by the method of claim 11, claim 12, claim 13, or claim 14.

10

15

20